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Abstract Non-invasive prenatal testing (NIPT) has been integrated into clinical care at a time when patients and healthcare
providers increasingly utilize the internet to access health information. This study evaluated online direct-to-consumer information
about NIPT produced by commercial laboratories accessible to both patients and healthcare providers. A coding checklist captured
areas to describe content and assess concordance with clinical guidelines. We found that the information presented about NIPT is
highly variable, both within a single website and broadly across all websites. Variability was noted in how NIPT is characterized,
including test characteristics and indications. All laboratories offer NIPT to test for common sex chromosome aneuploidies, although
there is a lack of consistency regarding the conditions offered and information provided about each. Although indicated for a subset
of women at increased risk of aneuploidy, some laboratories describe the use of NIPT for all pregnant women. A subset of laboratories
offers screening for microdeletions, although clinical practice guidelines do not yet recommend for general use for this indication.
None of the online materials addressed the ethical issues associated with NIPT. This study highlights the need for clear, consistent,
and evidence-based materials to educate patients and healthcare providers about the current and emerging applications of
NIPT.
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Non-invasive prenatal testing (NIPT) uses cell-free fetal DNA
(cff DNA) to assess the risk of fetal trisomy 21, trisomy 18 and
trisomy 13, with a greater sensitivity and specificity than
conventional serum analyte screening tests (Bianchi et al.,
2014; Norton et al., 2012). In addition, NIPT can be used to
identify sex chromosome aneuploidies (SCA) that formerly
could be detected only by using invasive diagnostic proce-
dures. Currently, as outlined by clinical practice guidelines,
NIPT is indicated for these conditions and for pregnant women
who, on the basis of maternal age, reproductive history or a
positive finding on other screening tests, are at increased risk
for fetal aneuploidies (ACOG, 2015; Benn et al., 2013; Devers
et al., 2013; Dondorp et al., 2015; Gregg et al., 2013).
However, the use of NIPT in the general obstetric population is
forthcoming (Greene et al., 2013; Wapner et al., 2015).
NIPT can be differentiated from conventional screens in
two main ways. First, it can screen for a larger number
of chromosomal aneuploidies than serum analyte screens can.
Furthermore, because of the rapid pace of cff DNA technology,
the capability of NIPT has quickly expanded to include the ability
to identify subchromosomal variants - specifically, a set of
microdeletions associated with clinical phenotypes (Wapner et
al., 2015). It is anticipated that detailed genetic informationwill
become accessible when NIPT is used to conduct genome-wide
fetal aneuploidy detection (Bianchi et al., 2012). Research and
development has progressed despite active debate about
whether and how to utilize NIPT for these purposes (Allyse and
Chandrasekharan, 2015; Norton et al., 2013).
Second, unlike the case for other prenatal genetic tests,
industry has had an important role in the development
and introduction of NIPT (Allyse and Chandrasekharan, 2015;
Baudhuin et al., 2012). The stage for the introduction of NIPT
was set by the small number of commercial laboratories that
initially developed the technology. Each laboratory brought its
own proprietary platform to market, offering a screening
package to identify a unique set of genetic conditions with
different sensitivities, specificities and cut-off values (Allyse
et al., 2013; Mozersky and Mennuti, 2012). There is concern
that the unprecedented dynamic of industry and commercial
factors in the initial and continued development of prenatal
genetic technologies will lead to practical and ethical issues
which, in turn, will influence patients’ access to NIPT in
addition to the type and volume of information that can be
obtained about the fetus (Agarwal et al., 2013).
The pace and context in which NIPT has emerged raises
important questions about how patients and healthcare
providers access information about this new screening option.
Studies show that the internet is now an important source of
medical information (Fox and Duggan, 2013). Currently, there is
a large number of online resources available fromwhich readers
can learn about NIPT. These resources include open access
peer-reviewed medical journal articles, clinical practice guide-
lines, public websites with evidence-based medical informa-
tion, and social media sites, all of which are subject to various
degrees of review (ranging from thorough to moderate,
minimal, or often no quality review). This information also
includes marketing materials offered by commercial laborato-
ries that developed NIPT, which are among the lead results on
an internet search on the subject (Mercer et al., 2014).Patients are one population turning to the internet for
medical information, including women who are currently
pregnant or are considering a pregnancy. Studies of internet
usage by select populations of pregnant women have shown
that some use the internet to obtain information about the
pregnancy prior to their prenatal visit and to supplement
information provided by their healthcare provider after their
visit (Huberty et al., 2013, Song et al., 2012); they also use it
to find information about prenatal genetic testing options
(Farrell et al., 2014, Farrell et al., 2015a). In addition,
internet-based materials produced by commercial laborato-
ries have become an important resource for pregnant
women to gain information about NIPT (Farrell et al., 2014).
Healthcare providers are another population who utilize
web-based materials to acquire knowledge and develop
clinical practice patterns around the use of new tests,
procedures and therapeutics (Bennett et al., 2004; Casebeer
et al., 2002). Some physicians use internet-based educa-
tional materials more frequently than traditional, printed
materials (Google/Hall and Partners, 2009). Web-based
information developed by commercial laboratories has also
become an educational resource for obstetric healthcare
providers to develop and update their knowledge base about
NIPT (Farrell et al., 2016). While online educational tools are
an ideal mode through which to provide continuing educa-
tion for physicians, there is concern about the biases that
can be introduced when industry has a role in medical
education (ACOG Committee on Ethics, 2012).
Despite the growth of NIPT and the role of the internet as a
source of information about new tests, little is known about
the content of online information produced by commercial
laboratories about this new screening option. Given the
availability of direct-to-consumer information on the internet
about NIPT (Mercer et al., 2014) and trends in how pregnant
patients and healthcare providers utilize electronic educa-
tional resources, we examined the online information pre-
sented by leading commercial laboratories regarding this new
screening test. The objectives of this study were to evaluate
the content of these websites and determine whether the
information they presented was accurate, comprehensive and
consistent, both in terms of characterizing NIPT and current
clinical guidelines about its use.Materials and methods
An internet search using the term ‘non-invasive prenatal
testing’ in Google, Yahoo! and Bing was conducted during
April 2015 to identify commercial laboratories that currently
offer NIPT. At the time of the search, five US commercial
laboratories were identified (Table 1).
Websites provided information targeted at two distinct
consumer groups: patients and healthcare providers. Screen
shots of each commercial laboratory’s website were saved
as PDF files and labelled with the date of capture. These
images contained information visible to all readers, including
patient-specific and healthcare provider-specific resources.
The files were separated by content targeted at specific
reader groups for combined and categorical analyses.
We utilized content analysis methodology (Morgan 1993)
to evaluate the websites in our study sample. This
methodology involves using a coding checklist to categorize
Table 1 NIPT commercial laboratories in study sample.
Name NIPT product URL
Ariosa Diagnostics HarmonyTM Prenatal Test http://www.ariosadx.com/expecting-parents/
http://www.ariosadx.com/healthcare-professionals/
Illumina, Inc. verifi®Prenatal Test http://www.illumina.com/clinical/reproductive-genetic-health/
patients/non-invasive-prenatal-screening.html
http://www.illumina.com/clinical/reproductive-genetic-health/
healthcare-professionals/non-invasive-prenatal-testing.html
Integrated Genetics informaSeqSM Prenatal Test https://www.labcorp.com/wps/portal/integratedgenetics
Natera, Inc. PanoramaTM Prenatal Screen http://www.panoramatest.com/en/expecting-parents/about-panorama
http://www.panoramatest.com/en/healthcare-provider/overview
Sequenom MaterniT21®PLUS Prenatal Test https://laboratories.sequenom.com/patients/maternit21-plus/
https://laboratories.sequenom.com/providers/maternit21-plus/
NIPT = non-invasive prenatal testing.
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quantified. The coding checklist was developed by building
upon the checklist used in our previous website analysis
(Mercer et al., 2014) to meet the specific objectives of this
study. Specifically, the coding checklist was structured to
capture key content areas drawn from clinical guidelines
regarding indications of NIPT published by the American
College of Obstetricians and Gynecologists, the American
College of Medical Genetics and Genomics, the National
Society of Genetic Counselors and the International Society
for Prenatal Diagnosis (ACOG, 2015; Benn et al., 2013;
Devers et al., 2013; Gregg et al., 2013). It was also
constructed to capture content related to counselling,
decision-making, informed consent, values and ethics, as
outlined in the policy statement of the American Society of
Human Genetics and the European Society of Human
Genetics (Dondorp et al., 2015). The manner in which
each laboratory categorized (screening, diagnostic, not
specified) and described (non-invasive, assessment of spe-
cific conditions, sensitivity, specificity, false-positive and
false-negative rates, and analytic method) NIPT - as well as
cost, insurance coverage, and the return of results to the
clinician - was analysed. Links to downloadable brochures or
checklists were also captured for analysis. Content areas of
the coding checklist are summarized in Table 2.
Two members of the research team independently used
content analysis methodology (Morgan, 1993) to evaluate
and code the content of the websites. Members of the
research team met to compare coding and develop a
consensus between the coders.
In addition, the readability of the content of each
commercial laboratory website targeted at patients was
assessed using the Flesch Reading Ease (FRE) and
Flesch-Kincaid Grade Level formulas (Aliu and Chung, 2010;
Kars et al., 2008). The content of each website was
downloaded into Microsoft Word, which has a built-in tool
to compute FRE and Flesch-Kincaid Grade level scores.
Reading ease was evaluated on a scale of 0-100 by using the
FRE score: the lower the score, the more difficult the
content. Adapting the FRE scores as per D’Allesandro
(D’Allesandro et al., 2001), the following designations were
used: (i) easy reading, N80 (less than a sixth-grade reading
level); (ii) adequate or standard reading, 60-80 (sixth- toeighth-grade level); and (iii) difficult reading, b60
(ninth-grade level or greater). The Flesch-Kincaid Grade
Level formula, which translates reading scores into a reading
grade level (Aliu and Chung, 2010), was calculated for the
patient-directed content of each commercial laboratory
website.
The final data were entered into an Excel database
and exported to the Statistical Package for Social Sciences
(SPSS) Version 19 (IBM Corp., USA) for statistical analyses.
Frequencies of informational content of all websites
were calculated across and within laboratory websites for
targeted reader groups.
Results
The commercial laboratory websites were among the
first three pages of listings based on the search term
‘non-invasive prenatal testing’ on all three search engines.
Description of NIPT
All five commercial laboratories described their product as a
non-invasive prenatal test that could analyse cff DNA in
maternal blood starting from 9-10 weeks’ gestation. Labo-
ratories varied in the manner in which they described NIPT.
Four laboratories described NIPT as a screening test; two of
these laboratories included this description in both patient
and healthcare provider materials and one included it in
the patient materials only. The fourth laboratory referred
to NIPT as a screening test in the healthcare provider
materials, but described it as a diagnostic test in an
educational video link on the patient-directed website,
although in another location in the patient-directed mate-
rials it mentioned that additional confirmatory testing was
recommended (although the term ‘screening’ was not used).
The remaining laboratory did not specifically categorize the
test as a screening or diagnostic test in either the patient or
healthcare provider content.
Information regarding the specificity and sensitivity of
the screening test varied among the laboratories’ websites.
Four of the five laboratories discussed the chance of a
false-positive result in both patient and healthcare provider
Table 2 Content areas of coding checklist.
Content
Description of NIPT
Categorization
Non-invasive blood test
Analytic method
Sensitivity
Specificity
False positive
False negative
Cost and insurance
Conditions assessed
Autosomal aneuploidies
Sex chromosome aneuploidies
Microdeletion syndromes
Fetal sex
Indications
Advanced maternal age
Reproductive history
Second tier test
General obstetric population
Report of results
Risk level
Positive/negative
Detected/not detected
Not reportable
Recommends confirmatory diagnostic testing
Patient education and counselling
Role of healthcare provider in testing process
Informed consent
Values
Ethical considerations
Educational resources/links
NIPT = non-invasive prenatal testing.
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false-negative result. One included this information in both
patient and healthcare provider content and the other did so
in patient material only. The content of the five laborato-
ries’ websites is summarized in Table 3.Conditions assessed using NIPT
Autosomal and sex chromosome aneuploidies
The laboratories consistently presented information
about the use of NIPT to test for common autosomal
aneuploidies. Across the board, all laboratories included
information about the use of NIPT for trisomy 21, trisomy 18
and trisomy 13, in both patient and provider materials.
While all laboratories provided information about the
utilization of NIPT to identify SCA, some variability was
noted in content specific to these conditions. Each of the
laboratories included information about Klinefelter syn-
drome and Turner syndrome in materials for both healthcare
providers and patients. Four laboratories addressed the use
of NIPT for Triple X in both the patient and provider
materials. The remaining laboratory included this informa-
tion in the provider materials only. Four of the fivelaboratories reported that their NIPT platform could assess
fetal sex in both patient and healthcare provider content
(Table 3).
Microdeletion syndromes
Three of the laboratories offered screening for
microdeletion syndromes and presented information about
this capability. Two laboratories addressed the use of NIPT
to detect 1p36 deletion syndrome, Cri-du-chat syndrome,
Prader Willi syndrome, and 22q11 deletion syndrome. This
information was included in content targeted at both
patients and healthcare providers. The third laboratory
addressed the use of NIPT for these syndromes in the
healthcare provider materials only. Information regarding
the use of NIPT to detect Angelman syndrome was presented
by two laboratories; in both cases, this information was
included in both patient and provider materials. Reporting
on testing for other microdeletions, including 11q, 8q, and
4p-, varied across laboratories.
Indications for NIPT
Laboratories varied in their presentation of information
regarding indications for NIPT. Three laboratories stated
that NIPT is indicated for women who are of advanced
maternal age. The remaining two laboratories indicated
that NIPT is available for women of all ages, regardless of
age-related aneuploidy risk. Reproductive history was noted
as an indication by four of the laboratories, although only
one laboratory included this information in the patient
material. Four laboratories presented NIPT as a follow-up
test that could be used after a positive serum-screening test
or after a sonographic finding of a fetal anomaly. Two of
those laboratories included information about this indication
in both patient and healthcare provider materials. Of the
two remaining laboratories, one addressed this only in the
patient information, and the other only in the healthcare
provider information (Table 3).
Report of test results
All five laboratories presented information on the manner in
which NIPT results are reported in content targeted at both
patients and providers. Three laboratories described that
results are reported as a risk level (e.g. high risk or low risk)
and included this information in both patient and provider
materials. One laboratory described the report of a
‘positive’ or ‘negative’ for trisomy 21, trisomy 18 and
trisomy 13, and an ‘additional finding’ for other chromo-
somal abnormalities. The remaining laboratory reported
results as ‘aneuploidy detected,’ ‘no aneuploidy detected’
and ‘aneuploidy suspected (borderline value).’ Only one
addressed the possibility of a non-reportable result, and this
information was only provided in the patient material. All
laboratories recommended diagnostic testing to confirm a
result that indicates the presence of a chromosomal
abnormality: two laboratories provided this information in
both patient and healthcare provider materials, two provid-
ed it in the patient materials but not in the healthcare
provider materials, and one provided it in the healthcare
provider materials but not those for patients.
Table 3 Review of commercial laboratories’ website content. a
Content Laboratory 1 Laboratory 2 Laboratory 3 Laboratory 4 Laboratory 5
Patient HCP Patient HCP Patient HCP Patient HCP Patient HCP
Description of NIPT
Screen - X X X X X - - X -
Diagnostic X - - - - - - - - -
Unspecified - - - - - - X X - -
False positive - - X X X X X X X X
False negative - - - - X X X - - -
Conditions assessed
Trisomy 21 X X X X X X X X X X
Trisomy 21 description X - X - - - - - X -
Trisomy 18 X X X X X X X X X X
Trisomy 18 description X - X - - - X - X -
Trisomy 13 X X X X X X X X X X
Trisomy 13 description X - X - - - X - x -
Klinefelter syndrome X X X X X X X X X X
Klinefelter description X - X - - - X - - -
Turner syndrome X X X X X X X X X X
Turner description X - X - - - X - - -
Triple X X X X X X X X X - X
1p36 deletion - X - - X X X X - -
Cri du chat syndrome - X - - X X X X - -
Prader–Willi syndrome - X - - X X X X - -
22q11 - X - - X X X X - -
Angelman syndrome - - - - X X X X - -
Fetal sex X X X X X X X X - -
Indications
All populations - - - - X X - - X X
AMA X X - X - - X X - -
Reproductive Hx X X X X X - X X - -
F/u positive screen X X - X X - X X - -
F/u positive U/S X X - X - - X X - -
Report of results
Risk level - - X X X X - - X X
Positive/negative - - - - - - X X - -
Aneuploidy detected/not X X - - - - - - - -
Reports no result - - - - X - - - - -
Confirmatory testing X X X - X X - X X -
Education/counselling
Role of HCP X X X X X X X X X X
Questions for HCP - - X - - - X - X -
Electronic form - - - - X - - - - -
Additional resources/links - X X - X X X - X -
Decision aid - - - - - - - - - X
Informed consent X X X - - X - - - -
Insurance/financial assistance X X X X X - X X X X
AMA = advanced maternal age; F/u = follow-up; Hx = history; HCP = healthcare provider; NIPT = non-invasive prenatal testing; U/S = ultrasound.
a Laboratories are not listed in any particular order.
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All laboratories provided information on the role of the
healthcare provider in pre- and post-test patient counselling
in both patient and provider materials. In addition, all
laboratories provided links or down-loads of additional
educational resources. Three laboratories provided a list ofquestions that patients could bring to their prenatal visit
to facilitate discussions about NIPT with their healthcare
provider. One laboratory provided an electronic form for
patients to enter their contact information and that of their
provider so that the laboratory could share this information
with the designated provider to help initiate discussions
about NIPT. All five laboratories provided resources and/or
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genetic conditions. Most were focused on trisomy 21,
trisomy 18 and trisomy 13. Some websites included informa-
tion regarding SCA and microdeletions. Sources of informa-
tion included documents developed by the commercial
laboratories, professional organizations and advocacy
groups. Three laboratories had links to clinical practice
guidelines; two of these laboratories offered microdeletion
screening, although such indications were not addressed in
the referenced document. One of the five laboratories
provided downloadable tools intended for use by healthcare
providers to assist in patient education and counselling.
Three laboratories included information about informed
consent: one provided the information to healthcare
providers only; the second provided the information in
both patient and provider materials, and the third pro-
vided the information in patient-directed materials only.
None of the website content provided by the commercial
laboratories addressed personal values and ethical con-
siderations as they relate to the decision-making process
for NIPT.
All five laboratories included information regarding
insurance coverage or financial assistance for NIPT. Four
laboratories addressed these topics in both patient and
provider materials. The remaining laboratory included
financial information in the patient materials only. The
specific cost of the test was not reported by any of the
websites.
Readability of patient-targeted websites
Readability scores were determined for the patient-directed
material produced by the individual laboratories. All of
the patient-directed materials were written at a difficult
reading level, based on a mean FRE score of 41.8 (range
39.1-50.2). The mean Flesch-Kincaid Grade Level was 11.34,
and ranged from approximately the tenth-grade level (10.3)
to the college level (13.1).
Discussion
NIPT has been integrated rapidly into the delivery of
prenatal care, both in the USA and internationally. The
first stages of this process began at a time when medical
information on the internet increased exponentially, chang-
ing fundamental paradigms of how individuals access
information about new tests and procedures (McMullan,
2006). Furthermore, NIPT emerged during a time when
direct-to-consumer marketing initiatives by industry filled a
void when other educational resources about this new
screening option were not readily available. As a result,
the educational materials of commercial laboratories who
developed NIPT have become a source of information for
both pregnant women and obstetric providers (Farrell et al.,
2015a; Farrell et al., 2016). This is significant because of
how individuals seek and respond to direct-to-consumer
materials developed from healthcare companies. Specifical-
ly, studies show that some individuals perceive
direct-to-consumer materials as a reliable source of infor-
mation (DeLorme et al., 2010; Huberty et al., 2013; Menon
et al., 2002; Närhi, 2007; Peterson et al., 2003). This findingwas initially observed among those who were exposed to
such information on the television or in print advertisements
(Menon et al., 2002; Närhi, 2007). Studies show that this
perception may also carry over into consumers’ use of
internet-based marketing materials (DeLorme et al., 2010;
Huberty et al., 2013; Peterson et al., 2003). At the same
time, studies demonstrate how industry-developed educa-
tional materials may influence patients’ and healthcare
providers’ behaviours (ACOG Committee on Ethics, 2012;
Fogel and Teichman, 2014). Additional data are needed to
further understand the factors that influence readers’
opinions about direct-to-consumer materials and behaviours
in response to them. Yet, the studies that are currently
available shed light on how patients and physicians may
utilize industry-produced materials accessed online to learn
about new medical options. Given these factors, we
conducted a study to examine the content of information
contained about NIPT within the websites of commercial
laboratories.
The internet provides a novel interface for patients to
obtain information about new genetic technologies prior to
and following the potentially complex discussions that
take place during the clinical encounter. Such information
is particularly relevant in the context of obstetrics, where
healthcare providers face limited time and resources to
convey an increasing volume of information to pregnant
women about prenatal care and their genetic testing options
(Allyse et al., 2013; Farrell et al., 2015b). Web-based
information cannot replace the important discussions that
take place between a patient and her healthcare provider.
Yet, such information does play a vital role in how patients
frame not only their expectations and decisions about their
healthcare options but also requests of their healthcare
provider regarding the use of new tests and procedures
(Farrell et al., 2014).
This study of commercially developed websites highlights
the need for clear and consistent materials to educate
patients and healthcare providers about the current and
emerging applications of NIPT. For instance, overall, we
observed a high degree of variability in the presentation of
information about NIPT, both within and across the com-
mercial laboratory websites. This finding was most prevalent
among the materials developed for patients and was
independent of the different approaches and capabilities
of the NIPT platforms of each company. Some of the
commercially developed web materials accurately described
NIPT as a screening test; however, others did not. This
finding may not be an issue for healthcare providers who
have an existing knowledge base about prenatal screening
and diagnostic tests. Yet it raises concerns for patients who
use commercial laboratory materials to initially learn about
NIPT or to supplement their knowledge about this testing
option. This result is significant, as studies show that
patients often search internet sites targeted at healthcare
providers to obtain comprehensive or detailed information
for themselves (Wood et al., 2000). Thus, the variability of
information presented by the commercial laboratories about
NIPT may make it difficult for patients to gain an accurate
picture of the utility of this test.
Variability in the manner with which laboratory websites
described the indications of NIPT was also noted. The use
of NIPT to screen for common autosomal aneuploidies,
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accepted by professional organizations (ACOG, 2015; Benn
et al., 2013; Devers et al., 2013; Dondorp et al., 2015; Gregg
et al., 2013). All of the commercial web-based materials
presented information regarding screening for these condi-
tions. However, while the advantages of using NIPT to screen
for these conditions were emphasized across all marketing
materials, information about the limitations of NIPT was
limited. In general, website content highlighted screen
sensitivity and specificity for the detection of trisomy 21.
Yet there was limited discussion about sensitivity, specificity
or positive predictive value for trisomy 13, trisomy 18 or
other identifiable conditions, each having its own detection
and false-positive rates. Studies demonstrate that these
concepts remain important factors in a patient’s
decision-making about the utilization of the NIPT, despite
its superior performance compared with conventional
analyte screens (Farrell et al., 2015a; Tischler et al., 2011).
Overall, there was also less consistency regarding the
presentation of information about SCA. All laboratories
presented information about the use of NIPT to detect
Klinefelter syndrome and Turner syndrome. Yet there was
variation in the information presented about other SCA that
can be detected and are associated with known clinical
syndromes. This finding may be a reflection of the
proprietary decisions of the commercial laboratories and
the specific conditions they choose to assess, as well as of
their respective platform’s test performance for the condi-
tions. However, even among the laboratories that offer
testing for these other SCA, materials about these conditions
were not equally and consistently addressed in both the
patient and healthcare provider materials. The lack of
information about SCA is concerning, as patients are not as
familiar with these conditions as they are with others
(Agatisa et al., 2015; Lau et al., 2012). Furthermore,
healthcare providers have less experience in providing
counselling regarding physical and cognitive issues associat-
ed with SCA than they do for other conditions
(Cleary-Goldman et al., 2006). In conjunction with providing
information about SCAs, many of the websites highlighted
the ability of their screening platform to assess fetal sex.
The capability to detect fetal sex may be presented as an
advantage of NIPT by some (Farrell et al., 2014) but has
important medical and ethical implications that should also
be considered (Chandrasekharen et al., 2014; Chapman and
Benn, 2014).
Another finding was the variation in and across
the websites’ content regarding the use of NIPT for the
detection of microdeletions in addition to departures from
current clinical practice guidelines. Presently, clinical
practice guidelines do not recommend the general use of
NIPT for the detection of microdeletions. Yet, three of the
laboratories presented information on their websites about
their specific platform’s ability to detect certain
microdeletions. The differences among the laboratories’
microdeletion offerings and educational resources may be a
reflection of market incentives for commercial NIPT labora-
tories to provide large and unique testing platforms before
competing laboratories do (Agarwal et al., 2013; Hayden,
2012). However, both the lack of consistency in
the direct-to-consumer materials among the commercial
laboratory websites, and marketing NIPT to screen formicrodeletions, raises important concerns regarding the
pathways and oversight with which new genetic technologies
are introduced into obstetrics.
Of additional concern, we identified other areas of
discordance between applications marketed by commercial
laboratories and clinical practice guidelines for NIPT. NIPT is
currently recommended for a subset of the pregnant
population - specifically, women at increased risk for fetal
aneuploidy because of maternal age, reproductive history, a
positive analyte screening test, or an abnormal ultrasound
finding (ACOG, 2015; Benn et al., 2013; Devers et al., 2013;
Dondorp et al., 2015; Gregg et al., 2013). Yet two of the
laboratories marketed their platform for use by all pregnant
women. While this practice is forthcoming, it is currently not
supported by clinical practice guidelines.
Finally, we found that the web-based marketing mate-
rials presented two additional challenges. First, personal
values and ethical considerations form the basis of decisions
to undergo any form of prenatal genetic screening or testing
(Kuppermann et al., 2006; Lyerly et al., 2007). However, our
analysis revealed a paucity of information about the ethical
issues associated with NIPT. Second, specific to patients who
seek information in this manner, the readability of all of the
patient-directed materials on the commercial laboratory
websites did not meet the National Institutes of Health and
the American Medical Association’s criterion that general
public health information be written no higher than a
sixth-grade reading level (Cotugna et al., 2005). The
advanced reading level presents an additional challenge for
patients who use these online materials.
The current landscape of NIPT is poised to change with
the resolution of ongoing debates regarding intellectual
property between these laboratories and the capability of
new laboratories to perform the screening test (Agarwal et
al., 2013; Hayden, 2012). Unlike the case for other prenatal
screening options, commercial laboratories at the forefront
of cff DNA technology have taken the lead in shaping
the clinical debut and ongoing integration of NIPT into
patient care. The laboratories’ dual marketing messages, to
healthcare providers as well as patients, have been heard.
Patients are entering the clinical encounter aware of NIPT
and interested in incorporating it into their prenatal care
(Hill et al., 2012; Tischler et al., 201,). Thus, these
laboratories have set the stage for educating patients as
well as healthcare providers about NIPT, and integrating it
into prenatal care, independent of guidance from profes-
sional organizations. This endeavour will undoubtedly
continue as future applications of NIPT are offered by
existing laboratories as well as by new commercial enter-
prises entering the testing arena. Both now and as the
landscape of NIPT changes, it is critical that information
presented is consistent, comprehensive, and in accordance
with practice guidelines, as the stakes are high when
informed decision-making regarding reproductive choices is
at issue.
Although the internet is a dynamic platform for health
information, by using an established methodology of data
capture and analysis, we were quickly able to develop a
picture of the informational landscape provided by commer-
cial laboratories. Nonetheless, we are aware that this
content may be in flux. In addition, we recognize that
commercial laboratories are not the only source of
95Direct-to-consumer messages about NIPTinformation regarding NIPT. However, they represent an
integral resource for healthcare providers and patients (as
well as members of the general public) who look to the
internet for information about NIPT.
Conclusions
In light of parallel changes taking place regarding the role
of the internet in the delivery of healthcare, advances in
prenatal genetics, the industry’s role in direct-to-consumer
advertising, and the integration of NIPT into clinical care,
we assessed online resources provided by commercial
laboratories about this new screening test. Our findings
indicate that the information presented by commercial
laboratories is highly variable and, in some cases, does not
correlate with clinical practice guidelines. Overall, we
identified greater concordance between the sections of the
materials developed for healthcare providers and patients
specific to common autosomal aneuploidies, sex chromo-
some aneuploidies, and fetal sex but less consistency
between provider- and patient-directed materials that
address emerging applications of NIPT. These findings are
problematic for patients who seek information outside of the
clinical arena to inform important prenatal decisions and,
additionally, for healthcare providers who utilize this
information to learn about new technologies that affect
patient care. As the technology of NIPT advances, and with a
concurrent increase in online direct-to-consumer marketing
efforts, healthcare providers will be presented with addi-
tional challenges to ensure patients acquire the necessary
information to make informed, patient-centred decisions
about the use of NIPT. This study underscores the need for
accessible evidence-based, unbiased and comprehensive
information about NIPT for patients and providers, as well
as the need for established pathways and oversight, as
regards to how new genetic technologies are introduced into
prenatal care. Study findings also highlight that healthcare
providers should remain an integral source of accurate
and unbiased information for patients and utilize reliable
sources of continuing medical education to maintain their
competence. This is a prime opportunity for healthcare
providers and professional organizations to rise to the
challenge and develop educational resources that are
directed at patients and clinicians, address current indica-
tions, and adapt as new applications of cff DNA technology
emerge.
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